Published in Eur J Clin Pharmacol on November 11, 2008
Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin Pharmacol (2010) 1.71
Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol (2010) 1.66
Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood. Eur J Clin Pharmacol (2011) 0.81
CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome. Pharmgenomics Pers Med (2017) 0.75
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem (1994) 3.75
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol (2007) 3.36
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther (2006) 3.09
Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol (2008) 1.48
Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther (2007) 1.43
Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther (1998) 1.12
Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol (2006) 1.09
Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br J Clin Pharmacol (2008) 1.08
Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther (2001) 0.95
Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients. Eur J Clin Pharmacol (2001) 0.94
Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics (2002) 0.87
Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Br J Clin Pharmacol (1999) 0.84
Digitalis intoxication induced by paroxetine co-administration. Lancet (2006) 2.01
Mutations in EFHC1 cause juvenile myoclonic epilepsy. Nat Genet (2004) 1.98
Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol (2010) 1.81
Chloroquine in the Ugandan market fails quality test: a pharmacovigilance study. Afr Health Sci (2003) 1.74
4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics (2008) 1.52
Effect of dose timing in relation to food intake on systemic exposure to blonanserin. Eur J Clin Pharmacol (2010) 1.47
Association between major Multidrug Resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry (2007) 1.38
Mutations of neuronal voltage-gated Na+ channel alpha 1 subunit gene SCN1A in core severe myoclonic epilepsy in infancy (SMEI) and in borderline SMEI (SMEB). Epilepsia (2004) 1.24
Defective function of GABA-containing synaptic vesicles in mice lacking the AP-3B clathrin adaptor. J Cell Biol (2004) 1.22
Peer counselors' role in supporting patients' adherence to ART in Ethiopia and Uganda. AIDS Care (2011) 1.22
Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Br J Clin Pharmacol (2005) 1.21
Measuring adherence to antiretroviral treatment in resource-poor settings: the feasibility of collecting routine data for key indicators. BMC Health Serv Res (2010) 1.20
Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther (2005) 1.17
Voices on adherence to ART in Ethiopia and Uganda: a matter of choice or simply not an option? AIDS Care (2009) 1.15
Genomewide high-density SNP linkage analysis of 236 Japanese families supports the existence of schizophrenia susceptibility loci on chromosomes 1p, 14q, and 20p. Am J Hum Genet (2005) 1.11
Severe myoclonic epilepsy in infancy: clinical analysis and relation to SCN1A mutations in a Japanese cohort. Adv Neurol (2005) 1.10
Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br J Clin Pharmacol (2008) 1.08
Medicinal plants used by traditional medicine practitioners for the treatment of HIV/AIDS and related conditions in Uganda. J Ethnopharmacol (2010) 1.07
Factors predicting home storage of medicines in Northern Uganda. BMC Public Health (2014) 1.06
Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes. Br J Clin Pharmacol (2006) 1.06
Determination of fexofenadine enantiomers in human plasma with high-performance liquid chromatography. J Pharm Biomed Anal (2006) 1.06
Existing capacity to manage pharmaceuticals and related commodities in East Africa: an assessment with specific reference to antiretroviral therapy. Hum Resour Health (2009) 1.05
Mutational analysis of CACNA1G in idiopathic generalized epilepsy. Mutation in brief #962. Online. Hum Mutat (2007) 1.03
Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol (2006) 1.03
Prevalence of metabolic syndrome among patients with schizophrenia in Japan. Schizophr Res (2010) 1.02
Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol (2004) 1.01
Training for health services and systems research in Sub-Saharan Africa--a case study at four East and Southern African universities. Hum Resour Health (2013) 0.98
Genetics of idiopathic epilepsies. Epilepsia (2005) 0.97
Staphylococcal enterotoxin induces emesis through increasing serotonin release in intestine and it is downregulated by cannabinoid receptor 1. Cell Microbiol (2007) 0.97
The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. Clin Pharmacokinet (2005) 0.97
Liquid chromatographic determination of fexofenadine in human plasma with fluorescence detection. J Pharm Biomed Anal (2004) 0.96
Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults. PLoS One (2008) 0.95
The effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet Genomics (2011) 0.95
Gender differences in factors associated with suicidal ideation and depressive symptoms among middle-aged workers in Japan. Ind Health (2012) 0.94
The genetics of febrile seizures and related epilepsy syndromes. Brain Dev (2003) 0.94
Microchromosomal deletions involving SCN1A and adjacent genes in severe myoclonic epilepsy in infancy. Epilepsia (2008) 0.94
Nucleotide changes in the translated region of SCN5A from Japanese patients with Brugada syndrome and control subjects. Life Sci (2003) 0.94
Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations. Eur J Clin Pharmacol (2007) 0.93
Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography: application to pharmacokinetic study in relation to CYP2C19 genotypes. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.93
Acute toxicity effects of the methanolic extract of Fagara zanthoxyloides (Lam.) root-bark. Afr Health Sci (2003) 0.92
Patients with a sodium channel alpha 1 gene mutation show wide phenotypic variation. Epilepsy Res (2007) 0.90
Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. J Psychopharmacol (2011) 0.90
The difference in Mismatch negativity between the acute and post-acute phase of schizophrenia. Biol Psychol (2002) 0.89
Age-dependent modulation of hippocampal excitability by KCNQ-channels. Epilepsy Res (2003) 0.89
An assessment of Makerere University College of Health Sciences: optimizing health research capacity to meet Uganda's priorities. BMC Int Health Hum Rights (2011) 0.89
Remapping and mutation analysis of benign adult familial myoclonic epilepsy in a Japanese pedigree. J Hum Genet (2011) 0.88
Mortality in Dravet syndrome: search for risk factors in Japanese patients. Epilepsia (2011) 0.88
Different patterns of dipole source localization in gelastic seizure with or without a sense of mirth. Neurosci Res (2002) 0.88
Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.88
Effects of ryanodine receptor activation on neurotransmitter release and neuronal cell death following kainic acid-induced status epilepticus. Epilepsy Res (2005) 0.88
Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra-short-acting beta1-blocker. Drugs R D (2005) 0.87
Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration. Eur J Clin Pharmacol (2007) 0.87
Sexual dysfunction in Japanese patients with schizophrenia treated with antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry (2009) 0.87
Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol (2004) 0.87
Mutation (Ser284Leu) of neuronal nicotinic acetylcholine receptor alpha 4 subunit associated with frontal lobe epilepsy causes faster desensitization of the rat receptor expressed in oocytes. Epilepsy Res (2002) 0.87
Retrospective multiinstitutional study of the prevalence of early death in Dravet syndrome. Epilepsia (2011) 0.87
Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. Am J Med Genet B Neuropsychiatr Genet (2003) 0.87
Inverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disorders. Hum Psychopharmacol (2011) 0.86
Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry (2008) 0.86
A consortium approach to competency-based undergraduate medical education in Uganda: process, opportunities and challenges. Educ Health (Abingdon) (2014) 0.86
No association between dietary patterns and depressive symptoms among a community-dwelling population in Japan. Ann Gen Psychiatry (2012) 0.86
Intermittent use of sulphadoxine-pyrimethamine for malaria prevention: a cross-sectional study of knowledge and practices among Ugandan women attending an urban antenatal clinic. Malar J (2014) 0.86
Prevalence of SCN1A mutations in children with suspected Dravet syndrome and intractable childhood epilepsy. Epilepsy Res (2012) 0.86
No association between bone mass and prolactin levels among patients with schizophrenia. Hum Psychopharmacol (2011) 0.86
Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther (2005) 0.85
Effect of age and disease on bone mass in Japanese patients with schizophrenia. Ann Gen Psychiatry (2012) 0.85
Pharmacokinetics and pharmacodynamics of intravenous artesunate during severe malaria treatment in Ugandan adults. Malar J (2012) 0.85
Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers. Eur J Clin Pharmacol (2007) 0.85
Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia. J Clin Pharmacol (2003) 0.85
Genetic abnormalities underlying familial epilepsy syndromes. Brain Dev (2002) 0.85
Effects of interleukin-1beta on hippocampal glutamate and GABA releases associated with Ca2+-induced Ca2+ releasing systems. Epilepsy Res (2006) 0.85
Comparison of ankle-brachial pressure index and pulse wave velocity as markers of cognitive function in a community-dwelling population. BMC Psychiatry (2010) 0.85
A de novo KCNQ2 mutation detected in non-familial benign neonatal convulsions. Brain Dev (2008) 0.85
Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol (2006) 0.85
Sensitive determination of itraconazole and its active metabolite in human plasma by column-switching high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit (2006) 0.85
Sex-specific effects of subjective memory complaints with respect to cognitive impairment or depressive symptoms. Psychiatry Clin Neurosci (2014) 0.84
Comparison of prevalence of metabolic syndrome in hospital and community-based Japanese patients with schizophrenia. Ann Gen Psychiatry (2011) 0.84
Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. Br J Clin Pharmacol (2005) 0.84
Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients. Ther Drug Monit (2002) 0.84
Zonisamide at clinically relevant concentrations inhibits field EPSP but not presynaptic fiber volley in rat frontal cortex. Epilepsy Res (2005) 0.83
Association between plasma paroxetine concentration and changes in plasma brain‐derived neurotrophic factor levels in patients with major depressive disorder. Hum Psychopharmacol (2011) 0.83
Dietary patterns are associated with obesity in Japanese patients with schizophrenia. BMC Psychiatry (2014) 0.83
Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. Br J Clin Pharmacol (2009) 0.83
Protein kinase associated with gating and closing transmission mechanisms in temporoammonic pathway. Neuropharmacology (2004) 0.82
Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. Br J Clin Pharmacol (2006) 0.82
Ankle brachial pressure index as a marker of apathy in a community-dwelling population. Int J Geriatr Psychiatry (2011) 0.82
Body mass index and quality of life among outpatients with schizophrenia in Japan. BMC Psychiatry (2013) 0.82
Pharmacokinetics of fexofenadine enantiomers in healthy subjects. Chirality (2007) 0.82
Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve. Eur J Clin Pharmacol (2006) 0.82
CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics (2007) 0.82
Characteristics of the tree-drawing test in chronic schizophrenia. Psychiatry Clin Neurosci (2010) 0.82
Adolescent suicidality as seen in rural northeastern Uganda: prevalence and risk factors. Crisis (2011) 0.82
Depression increases the length of hospitalization for patients undergoing thoracic surgery: a preliminary study. Psychosomatics (2011) 0.82
Hearing impairment and cognitive function among a community-dwelling population in Japan. Ann Gen Psychiatry (2011) 0.82
Chewing-stick practices using plants with anti-streptococcal activity in a ugandan rural community. Front Pharmacol (2011) 0.81
Minor genetic variants of the dopamine D4 receptor (DRD4) polymorphism are associated with novelty seeking in healthy Japanese subjects. Prog Neuropsychopharmacol Biol Psychiatry (2009) 0.81
Lack of potassium current in W309R mutant KCNQ3 channel causing benign familial neonatal convulsions (BFNC). Epilepsy Res (2009) 0.81